The US Food & Drug Administration is expanding the range of drug development tools (DDTs) that can formally apply for qualification by the agency via a new pilot program: Innovative Science and Technology Approaches for New Drugs (ISTAND).
Announced by the agency on 30 November, the pilot program will allow sponsors and consortia to seek formal FDA qualification for tools like clinician-reported outcomes (ClinROs) through remote study...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?